Helsinn’s Family-Business Approach Goes Global In Cancer Care
Privately-owned Swiss firm preparing for its first solo launch in the US by doubling its sales force.
You may also be interested in...
ApolloBio signs on to take Inovio's HPV immunotherapy into China and Senju and Fosun sign China partnerships – all part of a wave of Chinese companies looking to bring innovative new medicines to the Greater China markets. Meanwhile, GSK signs on with Indian CRO Syngene.
The family-owned Swiss firm Helsinn has taken its pastoral business approach into the incubation of promising biotech startups by setting up a $50m fund for injecting seed capital into promising prospects.
Helsinn will help MEI Pharma advance its HDAC inhibitor pracinostat into Phase III development via a partnership worth up to $464m.